ArticleJournal of clinical medicine2014
Inflammation and Cell Death in Age-Related Macular Degeneration: An Immunopathological and Ultrastructural Model.
Article in Journal of clinical medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- The association between statin use and risk of age-related macular degeneration.Scientific reports · 2015Pooled it
- Differential Effects of Retinal Fatty Acids Under Oxidative Stress Reveal DHA's Susceptibility to Ferroptosis and Polarity Disruption in iPSC Derived RPE Cells.Stem cell reviews and reports · 2026Article
- Article
- AGE-RELATED RETINAL PIGMENT EPITHELIUM DISEASE: Clinical and Differential Features.Retina (Philadelphia, Pa.) · 2026Observational
- Oxidative Stress in Cataract Formation: Is There a Treatment Approach on the Horizon?Antioxidants (Basel, Switzerland) · 2024Review
- Stages, pathogenesis, clinical management and advancements in therapies of age-related macular degeneration.International ophthalmology · 2023Review
- Nanocarriers for the Delivery of Neuroprotective Agents in the Treatment of Ocular Neurodegenerative Diseases.Pharmaceutics · 2023Review
- Polymorphism rs11200638 enhanced HtrA1 responsiveness and expression are associated with age-related macular degeneration.Eye (London, England) · 2022Article
- Spotlight on pyroptosis: role in pathogenesis and therapeutic potential of ocular diseases.Journal of neuroinflammation · 2022Review
- Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.Ophthalmology science · 2022Article
- Damage-Associated Molecular Patterns (DAMPs) in Retinal Disorders.International journal of molecular sciences · 2022Review
- An Ultrastructural Perspective on Cell Death.Jordan medical journal · 2022Article
- Assessment of three successive treatments of ranibizumab on neovascular macular degeneration by OCT angiography.Experimental and therapeutic medicine · 2021Article
- Self-Assembling Tacrolimus Nanomicelles for Retinal Drug Delivery.Pharmaceutics · 2020Article
- Retinal pigment epithelium and age-related macular degeneration: A review of major disease mechanisms.Clinical & experimental ophthalmology · 2020Review
- Diet Mimicking "Fast Food" Causes Structural Changes to the Retina Relevant to Age-Related Macular Degeneration.Current eye research · 2020Article
- A low glycemic diet protects disease-prone Nrf2-deficient mice against age-related macular degeneration.Free radical biology & medicine · 2020Article
- Retinal and choroidal capillaries contribution to age-related macular degeneration (AMD) phenotypes in murine models of the disease.Ultrastructural pathology · 2020Article
- Interplay between reactive oxygen species and autophagy in the course of age-related macular degeneration.EXCLI journal · 2020Review
- Autoimmune-Mediated Retinopathy in CXCR5-Deficient Mice as the Result of Age-Related Macular Degeneration Associated Proteins Accumulation.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
The etiology of Age-related Macular Degeneration (AMD) remains elusive despite the characterization of many factors contributing to the disease in its late-stage phenotypes. AMD features an immune system in flux, as shown by changes in macrophage polarization with age, expression of cytokines and complement, microglial accumulation with age, etc. These point to an allostatic overload, possibly due to a breakdown in self vs. non-self when endogenous compounds and structures acquire the appearance of non-self over time. The result is inflammation and inflammation-mediated cell death. While it is clear that these processes ultimately result in degeneration of retinal pigment epithelium and photoreceptor, the prevalent type of cell death contributing to the various phenotypes is unknown. Both molecular studies as well as ultrastructural pathology suggest pyroptosis, and perhaps necroptosis, are the predominant mechanisms of cell death at play, with only minimal evidence for apoptosis. Herein, we attempt to reconcile those factors identified by experimental AMD models and integrate these data with pathology observed under the electron microscope-particularly observations of mitochondrial dysfunction, DNA leakage, autophagy, and cell death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.